FDA “Case Studies” On Dosing Problems Include Lotronex, Crestor

FDA believes that use of an exposure-response analysis to establish the optimal dose of GlaxoSmithKline's irritable bowel syndrome agent Lotronex would have prevented its withdrawal

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet